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Abstract
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Successful restoration of vision in human patients with gene therapy affirmed its promise to cure
ocular diseases and disorders. The efficacy of gene therapy is contingent upon vector and mode of
therapeutic DNA introduction into targeted cells/tissues. The cornea is an ideal tissue for gene
therapy due to its ease of access and relative immune-privilege. Considerable progress has been
made in the field of corneal gene therapy in last 5 years. Several new gene transfer vectors,
techniques and approaches have evolved. Although corneal gene therapy is still in its early stages
of development, the potential of gene-based interventions to treat corneal abnormalities have
begun to surface. Identification of next generation viral and nanoparticle vectors, characterization
of delivered gene levels, localization, and duration in the cornea, and significant success in
controlling corneal disorders, particularly fibrosis and angiogenesis, in experimental animal
disease models, with no major side effects have propelled gene therapy a step closer towards
establishing gene-based therapies for corneal blindness. Recently, researchers have assessed the
delivery of therapeutic genes for corneal diseases and disorders due to trauma, infections,
chemical, mechanical, and surgical injury, and/or abnormal wound healing. This review provides
an update on the developments in gene therapy for corneal diseases and discusses the barriers that
hinder its utilization for delivering genes in the cornea.
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1. Introduction
Gene therapy has advanced in leaps and bounds since its introduction to medicine almost 20
years ago as a query on gene therapy in the United States National Library of Medicine
database PubMed yields over 124,000 articles from almost all medical disciplines. In the
field of ophthalmology, gene therapy has shown astounding success. Recently, a
breakthrough was attained in the restoration of vision in human patients suffering from
Leber’s congenital amaurosis using gene replacement therapy in the retinal pigment
epithelium (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Maguire et
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al., 2009; Simonelli et al., 2010). This plainly gives credence to the potential of gene therapy
to cure diseases of the ocular system and prevent blindness.
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Current treatments for corneal disorders include various pharmacological agents and
surgical approaches depending on the cause, extent, and type of corneal damage.
Conventional drug therapies to treat corneal disorders provide only short-term relief, require
repeated application, cause side effects, and are often ineffective. More importantly they do
not correct the cause of the problem but merely suppress symptoms. Conversely, gene
therapy fixes the root of the problem, provides long-term cure, and does not require repeated
applications or clinic visits. However, at present no gene therapy modalities are available for
corneal diseases. The cornea is an ideal tissue for gene therapy due to its ease of access and
relative immune-privilege. As it is a transparent tissue and devoid of blood vessels, it can be
readily monitored visually. These properties also allow for the administration of therapeutic
genes into corneal cells with relative ease. The cornea is well suited for conducting ex vivo
gene therapy strategies because it can be maintained in culture for a long time. The arduous
task of developing novel gene-based modalities for cornea has greatly improved due to
increased comprehension of acquired and inherited corneal diseases in terms of molecular
mechanisms and pathogenesis. Numerous approaches employing different viral and nonviral vectors and techniques to introduce genes into the cornea in vitro, ex vivo, and in vivo
have been tested. Among viral vectors, adenovirus, adeno-associated virus (AAV),
retrovirus, and lentivirus vectors have been found to efficiently transport genes into corneal
tissue. However, concerns over safety and immunogenicity have limited their use. Nonviral
vectors including plasmid DNA, lipids, polymers, and nanoparticles are generally safe but
often found less efficient than their viral counterparts. Various physical techniques such as
topical administration, gene gun, electroporation, intrastromal injection, and iontophoresis
have been used to augment delivery of both viral and nonviral vectors. However, none of
these vectors or techniques is ideal, and each has its benefits and shortcomings. Herein we
provide a comprehensive review of corneal gene therapy approaches tested in the past six
years and a brief general overview of vectors. A detailed overview of gene therapy vectors
and their mode of action can be found in our previous corneal gene therapy review (Mohan
et al., 2005).

2. Gene therapy vehicles for the cornea
2.1 Viral vectors
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Viruses have been used since the dawn of gene transfer technology to deliver genes into
different cells and tissues. Viruses were used as a vector in about 70% of gene therapy
clinical trials (Young et al., 2006). Adenovirus (AV), adeno-associated virus (AAV),
retrovirus, and lentivirus have been found to efficiently transport genes into the cornea.
Nevertheless, each of these vectors has its own limitations. Adenovirus and retrovirus can
successfully deliver genes into the cornea for short periods of time with mild-to-severe
inflammatory responses. However, both of these vectors are of limited use for corneal gene
therapy because of their inability to transduce low/non-dividing cells such as corneal
endothelium and keratocytes, and induction of immune reactions. AAV and disabled
lentivirus vectors offer better alternatives for delivering genes into corneal keratocytes and
endothelium because of their ability to transduce slow/non-dividing cells and ability to
provide long-term transgene expression. The origin of lentivirus vectors (equine infectious
anemia virus and HIV) remains a major concern and significantly dampens enthusiasm for
its use in human patients. Among viral vectors, AAV appears to be a good choice for
corneal gene therapy because of their potency and safety profile. Recombinant AAV vectors
have shown great promise for ocular gene therapy and restoring vision in patients with no
major side effects.

Prog Retin Eye Res. Author manuscript; available in PMC 2013 January 1.
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2.1.1 Adenovirus—Recombinant forms of AV have been engineered and utilized in gene
transfer studies in the past (Mohan et al., 2005). In sum, first-generation AV vectors lack the
E1 gene region rendering them unable to replicate although they can proliferate in cell lines
that provide E1 gene product. Second-generation AV vectors lack E1, E2, and E4 viral
genes leading to less immunogenicity than first-generation vectors. In third-generation AV
vectors, the AV viral genome is absent and only ITR sequences and packaging genes are
present thus giving the name gutless or high-capacity vectors. Third generation AV vectors
are able to carry larger gene inserts and are less immunogenic but require a helper virus. In
order to reduce helper virus contamination, Cre/lox-P system and 293 cells stably
transfected with Cre recombinase are utilized and have been shown to decrease helper virus
contamination to <0.01% (Palmer and Ng, 2005). However, even this minimal level of
contamination may be detrimental in clinical scenarios where large doses are required.
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Multiple studies have examined the efficiency of AV vectors for corneal gene therapy
(Mohan et al, 2005). AV vector was found most efficient in transducing murine cornea
compared to equine immunodeficiency, lenti and bacculovirus vectors (Beutelspacher et al.,
2005). Recently, AV vectors have been shown to deliver genes successfully into mouse
corneal stroma and endothelium under control of cytomegalovirus immediate-early promoter
(CMV) (Yu et al., 2007). The Ritter group has also reported cytokine or growth factor gene
transfer with AV vector in rodent corneas (Ritter et al., 2007; Gong et al., 2007a; Gong et
al., 2007b). AV vectors provide short-lived transgene expression and also demonstrate
moderate to severe immune reaction apart from other side effects and (Yu et al., 2007; Ritter
et al., 2007; Gong et al., 2007a; Gong et al., 2007b; Sharma et al., 2010a). Recombinant AV
vectors have potential use in corneal gene therapy to over-express proteins in the corneal
epithelium particularly in scenarios such as diabetes mellitus where transient gene
expression is desirable. However, the ephemeral nature of AV vectors discourages its
application in gene-based treatment for inherited gene defects (Saghizadeh et al., 2010).
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2.1.2 Adeno-associated virus—Among 110 identified AAV serotypes, to date only
serotypes 1–10 have been used for gene therapy. AAV vectors have demonstrated high
transduction efficiency and long-term transgene expression in the retina, cornea, and many
non-ocular tissues in vivo (Alexander and Hauswirth, 2008; Gao et al., 2005; Surace and
Auricchio, 2008 and references therein). AAV2 has been tested more in-depth compared to
other AAV serotypes for gene therapy although each serotype has shown unique
transduction patterns for various cells/tissues. AAV6, -8 and -9, especially, have the ability
to mediate whole-body gene transfer efficiently (Ghosh et al., 2007; Pacak et al., 2006). The
variation in gene transfer by different AAV serotypes is likely due to the interactions
between host-cell receptor and viral capsid (Van Vliet et al., 2008). Structural variations in
the capsid region of different AAV serotypes enable each serotype to bind different cell
surface receptors. For instance, AAV serotypes 4, 5, and 6 use sialic acid (Wu et al., 2006)
whereas AAV 8 and 9 use laminin receptors to enter cells (Akache et al., 2006). This led to
the development of hybrid AAV vectors as a variety of pseudopackaged vectors were
produced using transencapsidation of the AAV2 genome into the capsid of AAV1–9. These
next generation hybrid vectors AAV2/1–9, displayed much greater transduction efficiency
compared to AAV2/2 in ocular tissues of various animal models (Surace and Auricchio,
2008). It is important to note that a great deal of variation in transduction efficiency, tissue
preference, first transgene appearance timing, and duration was observed in studies
performed with various hybrid recombinant AAV vectors (Surace and Auricchio, 2008).
Lebherz et al. (2008) also evaluated the gene delivery efficiency and expression stability of
AAV2/7, 2/8, 2/9, with AAV2/1, 2/2, 2/5 using enhanced green fluorescent protein (EGFP)
and rhesus erythropoietin as transgenes. After vector introduction into the eye via
intravitreal and subretinal injection, the authors demonstrated that AAV2/7 and 2/8 possess
superior long-term transduction ability (up to 6 months) in both retinal and anterior chamber
Prog Retin Eye Res. Author manuscript; available in PMC 2013 January 1.
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tissues including the iris, trabecular meshwork, and cornea, (Lebherz et al., 2008).
Subsequent studies with AAV2/6, AAV2/7, AAV2/8, and AAV2/9 vectors further
reinforced these finding for retinal tissue (Surace and Auricchio, 2008). In a similar fashion,
AAV2/8 and 2/9 demonstrated 5–100 fold superior transduction efficiency in non-ocular
tissues such as heart (Wang et al., 2005), brain (Broekman et al., 2006), skeletal muscle
(Wang et al., 2005), lung (Limberis and Wilson, 2006), and liver (Gao et al., 2006). We
compared the efficiency of AAV2/6, AAV2/8, and AAV2/9 serotypes for corneal gene
delivery using in vitro, in vivo, and ex vivo models to test a hypothesis that the relative
efficiency of AAV-mediated gene transfer in the cornea depends on serotype. In our first
study, the cellular tropism and transduction efficiency of AAV2/6, AAV2/8, and AAV2/9
vectors encoding alkaline phosphatase (AP) were tested using primary human corneal
fibroblasts cultures. We found the tested serotypes efficiently transduce human corneal
fibroblasts but that they differed in transduction efficiency. AAV2/6 displayed 30–50 fold
higher transduction efficiency compared to AAV2/8 or AAV2/9 (Fig. 1). A remarkably
positive and important finding was that none of the tested AAV serotypes induced
significant cell death or loss of cellular viability reaffirming that AAV vectors are safe for
the cornea (Sharma et al., 2010b). Interestingly, our subsequent studies with these vectors
using mouse cornea in vivo and human cornea ex vivo showed very different transduction
profiles compared to our in vitro investigations (Sharma et al., 2010c). Contrary to in vitro
findings, the order of transduction efficiency for the three tested vectors was found to be
AAV2/9 ≥ AAV2/8 > AAV2/6 (Fig. 2). These findings are not completely surprising as past
literature reports imply that in vitro gene delivery may differ from in vivo transduction
(Lipkowitz et al., 1999, Richter et al., 2000). However, the important take home message
from these studies is that in vivo testing of gene therapy vectors for the cornea is important
before making any conclusive inferences about vector efficacy. The one thing that remained
unchanged during in vitro, ex vivo and in vivo testing was the safety profile of tested AAV
serotypes. None of the three tested serotypes cause any significant side effects such as cell
death, loss of cellular viability, inflammation and/or noticeable immune reaction in the
cornea as measured with TUNEL and CD11b or F4/80 immunostaining (Fig. 3). Recently,
transgene expression in the corneal epithelium was detected up to 8 months with AAV2 in
the mouse eye suggesting that rAAV-delivered transgenes can persist for several months,
and possibly years, in vivo (Alexander and Hauswirth, 2008; Lai et al., 2007). Thus, using
AAV2/5 vector and a mouse model we performed time-dependent long-term animal
experiments to characterize delivered transgene expression and duration for the cornea in
vivo. Our ongoing studies showed different levels of transgene expression in the cornea in
vivo up to 10 months following topical vector application (Mohan et al., unpublished data).

NIH-PA Author Manuscript

The alterations in function, host range, and tissue tropism shown by different AAV
serotypes may be due to a degree of sequence variation within the capsid region (Van Vliet
et al., 2008). Furthermore, the differences in transduction profile are likely related to distinct
uptake and intracellular trafficking mechanisms of the various serotypes. In addition,
different serotype-specific ITR elements may also influence transgene expression. Various
studies report that the use of different serotypes or cross-packaging expands the tissue
tropism of rAAV vectors. Moreover, selective use of serotypes might allow for targeting
specific tissues. For example, an rAAV2 genome packaged in an AAV5 capsid (AAV2/5)
transduced photoreceptors and retinal pigment epithelial cells in the eye (Gao et al., 2005;
Surace and Auricchio, 2008) whereas AAV2-encapsidated vector transduced primarily
photoreceptors, and an AAV1-encapsidated vector transduced mainly retinal pigment
epithelial cells. Additionally, the utilization of different AAV serotypes may overcome the
problems associated with vector re-administration and preexisting immunity to rAAV2 in
humans (Adriaansen et al., 2006).

Prog Retin Eye Res. Author manuscript; available in PMC 2013 January 1.
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AAV vectors have emerged to the forefront in ocular gene therapy as they have been used in
a ground-breaking clinical trial to treat retinal diseases. Despite the proven potency and
safety of AAV vectors, relatively few studies have been performed to evaluate the potential
of AAV vectors for ocular surface gene delivery including the cornea. A recent study
compared rAV and rAAV tropism to human corneal cells in vitro and rabbit corneas in vivo.
It was noted that rAAV transduced more keratocytes while rAV transduction was detected
mostly in the epithelium. Interestingly, rAAV-mediated gene delivery led to lower GFP
expression compared to rAV. This may have specific clinical ramifications as choice of
vector may be dependent on transgene expression level or number of corneal cells requiring
gene transfer. For example, in corneal disorders of the epithelium like diabetes mellitus,
rAV may be more useful whereas rAAV may be more beneficial in stromal keratopathies
where keratocytes are targeted (Liu et al., 2008a). Using AAV2, RPE65 gene was delivered
to the retina of patients with Leber’s congenital amaurosis and successfully restored vision
(Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Maguire et al., 2009;
Simonelli et al., 2010). These studies clearly outline the safety and efficiency of AAV based
gene therapy for the retina leading the way for gene therapy for other ocular tissues
including the cornea.
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2.1.3 Retrovirus and lentivirus—Limited progress has occurred in the development
and/or testing of retro- and lenti-virus vectors. The “gutless” retroviral vectors were
developed by deleting the majority of the viral genome not required for infection. Further,
the risk of replication was curtailed by using a packaging cell line that employs gag/pol and
env from separate constructs, and by replacing the 5’ long terminal repeat (LTR) U3 region
in the viral genome with the CMV promoter (Lech and Somaia, 2008). LTRs, the control
center for gene expression, are sequences of DNA that flank functional genes found in
retroviral DNA and retrotransposons. Retroviruses such as HIV use LTRs to insert their
genetic sequences into the host genome. Even though modifications in these sequences have
been tested, the risk of insertional oncogenesis due to their random integration remains.
During a clinical trial for X-linked severe combined immunodeficiency treatment, retroviral
vector integration was noted near protooncogenes, and led to the development of T-cell
leukemia in 4 patients (Hacein-Bey-Abina et al., 2008), and the death of one of those
individuals (Herzog, 2010). This clearly reduces enthusiasm for adopting retrovirus for gene
therapy.
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The human immunodeficiency virus (HIV)-based lentiviral vectors have also been
investigated for corneal gene transfer. Lentivirus appears to be less toxic to the cell’s
genome than retrovirus (Montini et al., 2006). Current lentiviral vectors for gene therapy
lack the entire viral genome, and contain only the packaging signal and the cis-acting
elements, including the LTR. In an attempt to generate safer lentiviral vectors, the U3 region
of the 3’ LTR has been deleted. In recently generated lentiviral vectors, the endogenous
promoter has been replaced with a CMV/LTR hybrid promoter in an effort to improve
safety. Currently, glycoprotein of vesicular stomatitis virus is the mostly commonly used
env protein for lentiviral pseudotyping (Lech and Somaia, 2008). Not long ago it was
reported that transcriptionally active LTRs are chief contributors to genotoxicity and that
self-inactivating LTRs decrease the oncogenic potential thus improving the safety of
lentiviral vectors (Montini et al., 2009). Clinically, lentiviral vectors have yielded no reports
of serious adverse events (Williams and Coster, 2010). Selective studies have been
performed to evaluate the efficacy of lentiviral vectors for corneal gene therapy during the
past 6 years. Beutelspacher et al. (2005) compared self-inactivating HIV-1 and Equine
Infectious Anaemia Virus (EIAV) transduction efficiency in murine, rabbit, and human
corneal endothelial cells and found EIAV to be more effective than HIV-1 for corneal
endothelial gene therapy. Another study reported that a single injection of HIV-based
lentivirus into the anterior chamber of the rodent eye efficiently delivered transgene into the
Prog Retin Eye Res. Author manuscript; available in PMC 2013 January 1.
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corneal endothelium (Challa et al., 2005). Parker et al. (2007) demonstrated 80–90%
transduction of rat, bovine, and human corneal endothelial cells with lentiviral vector
expressing enhanced yellow fluorescent protein under control of the Simian virus type 40
early promoter. Bemelmans et al. (2009) demonstrated efficient transduction of keratocytes
up to 3 weeks in a pig model by injecting HIV-1 expressing GFP into a stromal pocket
created with a femtosecond laser.
2.2 Nonviral vectors
The introduction of plasmid DNA expressing therapeutic genes into target cells without the
use of viruses falls under the broad category of nonviral gene transfer methods. Nonviral
gene therapy is considered safer than viral gene therapy due to low toxicity,
immunogenicity, and pathogenicity. Additionally, plasmid vector production is
straightforward and cost-effective. Nevertheless, low transfection efficiency is a major
challenge. Many strategies have been developed and are in the preclinical pipeline to
improve plasmid delivery in cells. A brief description of popular techniques is given below.
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2.2.1 Microinjection technique—Introduction of plasmid via microinjection has led to
successful delivery of genes including GFP, interleukin (IL)18, Flt23k, endostatin, MMP14,
and vasohibin into various cells of the cornea (Kim et al., 2005; Jani et al., 2007; Lai et al.,
2007; Galiacy et al., 2011; Zhou et al., 2010; Sharma A, et al. IOVS 2010;51:ARVO EAbstract 2839,). Microinjections targeting different layers of the cornea have been
performed at various anatomic locations and include intrastromal, subconjunctival, and
directly into the anterior chamber (Singh et al., 2005; Kim et al., 2005; Lai et al., 2007; Zhou
et al., 2010; Yu et al., 2007; Sharma A, et al. IOVS 2010;51:ARVO E-Abstract 2839). A
recent study performed in mice demonstrated that bevacizumab treatment given via
intraocular injection was more efficacious than the subconjunctival (periocular) route
(Dratviman-Storobinsky et al., 2009). Intrastromal injection may be appropriate in the
treatment of acute corneal diseases as short-lived gene expression was detected in the cornea
following intrastromal injection (Hao et al., 2010). Conversely, subconjunctival injection
showed long-term stable transgene expression and may help to avoid the endophthalmitis
and cataract formation associated with intracameral injection (Kuo et al., 2009).
Microsurgical techniques also offer a feasible method of exploring gene function in corneal
disorders. For example, Kuo et al. (2008) showed successful transgene delivery in the
cornea in vivo using intrastromal lamellar implantation of a partially dried p-bFGF–
SAINT-18 complex composed of SAINT-18 and plasmid vector encoding reporter or FGF2
gene. This corneal gene transfer method permitted localized transgene delivery in the
cornea. It is thought that except for topical and subconjunctival administration, all other
gene delivery strategies to the cornea are invasive and compromise corneal integrity (Cheng
et al., 2007).
2.2.2 Electroporation—Electroporation, also known as electrogenetherapy or
electropermeabilization, makes use of high-intensity electrical pulses to form transient pores
in the cell membrane and is useful for gene delivery in both cultured eye cells and ocular
surface tissues in vivo. An advantage is large DNA constructs can be transported into cells
although specialized equipment is necessary (Williams and Coster, 2010). However, very
few studies have been reported in the cornea since 2005. Electroporation has the ability to
deliver foreign genes into the corneal epithelium as well as keratocytes (Zhou and Dean,
2007). Electrical current of 200 V/cm did not cause trauma, corneal edema, or inflammation
but introduced transgene at low levels. Higher electrical current resulted in enhanced gene
transfer but also led to considerable corneal damage. Electrical current can cause irreversible
tissue damage as a result of thermal heating or Ca2+ influx due to disruption of cell
membranes. Electrically assisted gene delivery to the endothelium of ex vivo human corneas
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was recently described (He et al., 2010). Using custom-designed electrodes, two reporter
genes, EGFP and beta-galactosidase (βgal), were successfully transported into human
corneas in organ culture using eight 1-Hz 100-ms pulses of 125 mA square current.
Although efficiency was much lower than viral vector, low cell death and no remarkable
change in tight junction integrity of endothelial cells show its potential clinical application
(He et al., 2010). The electrotransfer of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) small interfering RNA (siRNA) and dextran macromolecules into mice corneal
epithelium in vivo using iontophoresis and electroporation individually and in combination
has been reported (Hao et al., 2009). Although both iontophoresis and electroporation
independently delivered macromolecules into the cornea, iontophoresis was found to be
more efficient and the combination of iontophoresis followed by electroporation was more
effective than both methods alone (Hao et al., 2009).
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2.2.3 Sonoporation—Sonoporation employs ultrasound waves to create pores in the
plasma membrane in order to deliver DNA to the nucleus. Ultrasound is effective for cell
transfection in vitro and in vivo (Liu et al., 2006). Transfection efficiency of this approach is
dependent on the transducer frequency, acoustic pressure, output strength, and pulse
duration of ultrasound treatment in addition to the use of contrast agents such as
microbubbles. Microbubbles were generated as contrast agents to not only enhance imaging
but also improve gene delivery efficiency by boosting cell permeability (Mitragotri, 2005).
Ultrasound-targeted microbubble destruction may hold great potential as a site-specific gene
transfer approach and has been used successfully in AAV-mediated gene transfection of
human RPE cells in vitro and rat retina in vivo (Li et al., 2009). Microbubbles generally
measure approximately 3 micrometers in diameter and are composed of a shell which houses
a gas core. Available commercially, microbubbles differ in shell composition (i.e. albumin,
galactose, lipid, polymers) and gas core (i.e. air, perfluorocarbon, nitrogen) (Lindner 2004).
A notable advantage of microbubbles is that they may be targeted to specific areas of
interest. One way to accomplish this is the addition of a tiered polymer coat to the shell and
subsequent covalent (i.e. carbodiimide-mediated amide) or noncovalent (i.e. biotin-avidin)
coupling of targeting ligands to the polymer coat (Klibinov 2006). The precise mechanism
by which gene transfection is enhanced by ultrasound-mediated destruction of carrier
microbubbles is not clear but may include shell fragmentation-induced cellular
microporation and micro-environment changes brought about by high-velocity pressure jets
or heat and free radical production (Lindner, 2004). Ultrasound facilitates gene transfer by
way of passive diffusion (Gao et al., 2007). The Sakamoto group demonstrated successful
gene delivery into rabbit cornea in vitro and in vivo by combining ultrasound and
microbubbles (Sonoda et al., 2006). The central cornea was injected with plasmid mixed
with perflutren protein and a probe was placed on the ocular surface for ultrasound (1 MHz,
120 s, 50% duty cycle, 1 to 2 W/cm2) exposure. The ultrasound and microbubbles greatly
increased transduction efficiency into keratocytes without tissue damage. GFP was
expressed in the stroma for up to 30 days and was limited to the area exposed to ultrasound
(Sonoda et al., 2006). However, multiple safety concerns of microbubble use including
instability in serum and infection risk of components such as human albumin limit its use.
Subsequent studies entailed the utilization of ultrasound with a newly developed contrast
agent, a bubble liposome made of polyethylenglycol modified liposome containing
perfluoropropane gas. Sonoporation coupled with the bubble liposome showed enhanced
transgene delivery into rabbit corneal epithelial cells and rat subconjunctiva (Yamashita et
al., 2007). Although these studies outline the potential of sonoporation for corneal gene
therapy, many parameters remain to be investigated.
2.2.4 Gene gun—Gene gun is a ballistic (also called bioballistic) gene transfer method. It
utilizes micron-sized biologically inert heavy metal (gold, silver or tungsten) particles and
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mechanical or macroprojectile (centripetal, magnetic or electrostatic) force. The bombarding
of DNA-coated particles on cells/tissues with high velocity results in gene transfer. Gene
delivery with gene gun depends on many factors such as amount of DNA-coated on
particles, temperature, amount of cells, amount of force, number of DNA-coated particles,
etc. Shallow penetration of particles, substantial cell damage, uncontrolled gene transfer,
high cost, access to internal organs, etc. are few among many limitations of this method. The
successful gene delivery in the cornea with gene gun has been reported (Hao et al. 2010).
Genes such as IL4 and IL10 plasmid DNA and opioid growth factor receptor (OGFr) have
been introduced into the corneal epithelium with this method (Bauer et al., 2006; Zagon et
al., 2006). Zagon and cohorts showed delayed corneal abrasion healing after gene gunmediated delivery of sense OGFr cDNA in rat eyes. Conversely, they found that antisense
OGFr cDNA over-expression by the same delivery method led to accelerated corneal wound
healing (Zagon et al., 2006). This study established the autocrine behavior of the OGF-OGFr
axis, its regulatory role in ocular surface wound healing, and its potential in gene therapy
approaches for corneal diseases where wound healing is impaired such as diabetic
keratopathy. In addition, it highlighted the gene gun technique as a valuable tool in
examining the role of genes in epithelial abnormalities (Zagon et al., 2006). Another
research group targeted plasmids expressing IL10 and IL4 to the mouse cornea in order to
determine immune modulation of HSV-1 infection. The expression of delivered genes was
limited to corneal epithelial cells and attenuated the clinical course of infection although
small numbers of F4/80+ and CD11b+ cells were noted with treatment (Bauer et al., 2006).
Thus the gene gun method may be of great benefit in the focal treatment of corneal epithelial
disorders as minimal transfection occurs in neighboring tissues. However, the technique, in
its present form, is in need of additional optimization before being adopted for use in the
clinic (Bauer et al., 2006). Furthermore, due to high corneal epithelial cell turnover,
transgene expression is transient.
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2.2.5 Controlled corneal dehydration—Recently we reported that controlled corneal
dehydration increases vector absorption in mouse and rabbit corneas in vivo and human
cornea ex vivo using a hairdryer following epithelial removal. Vectors expressing marker
gene were used to study the effect of corneal drying on gene transfer. As evident from the
data presented in Fig. 4, increased corneal drying with a hairdryer showed increased
transgene delivery in the mouse cornea in vivo. However, excessive dehydration may have a
negative impact on corneal integrity. Detection of significantly higher transgene delivery in
vivo after 50 seconds of corneal drying with moderate changes in corneal morphology
affirmed the promise of this simple technique for corneal gene therapy. High transgene
delivery was also observed after 30 seconds of drying without jeopardizing corneal
morphology and moderate gene delivery was noted after 10 or 20 seconds of drying with no
altered corneal morphology. This study revealed that controlled corneal drying modulates
gene delivery in the cornea presumably due to a change in corneal hydration. Thus, we
postulated that administration of efficient vector employing simple minimally-invasive
techniques is a novel approach for delivering therapeutic levels of genes in the cornea in
vivo (Mohan et al., 2010b).
2.2.6 Laser—Recently, a stromal pocket technique involving the use of the femtosecond
laser to introduce genes into the pig cornea ex vivo was reported (Bemelmans et al., 2009). A
stromal pocket 110 microns in depth was produced with a femtosecond laser and lentiviral
vector expressing GFP was injected. Histology of corneal tissue performed 5 days after
vector application showed wound closure and marker gene expression in the cells (most
likely keratocytes) around the corneal pocket. Interestingly, the levels of transgene
expression noted at day-5 remained up to 3 weeks (Bemelmans et al., 2009). This method
facilitates gene delivery into cells in a specific, targeted corneal region. However,
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femtosecond laser is known to induce intense wound healing and infiltration of
inflammatory cells in the rabbit cornea (Netto et al., 2007). Thus, the next step would entail
the translation of this procedure from an ex vivo model to an in vivo model and the
establishment of a safety profile.
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2.2.7 Chemicals—Scores of natural and synthetic chemicals have been tested to introduce
genes into corneal cells. In this review we provide a short description of more widely tested
lipids and polymers for delivering genes in the cornea. Among many lipids
dioleoyltrimethylammonium chloride (DOTMA), dioleoylphosphatidyl-ethanolamie
(DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyl dioctadecyl
ammonium bromide (DDAB), 3β-[N-(N’,N’-dimethylaminoethane) carbamoyl}cholesterol
(DC-cholesterol), and N-methyl-4(dioleyl) methylpyridinium chloride (SAINT-2) showed
promise for corneal gene therapy. A transfection solution prepared from five different lipids
showed 7–17% transgene delivery in corneal endothelial cells in vitro (Dannowski et al.,
2005). Our laboratory formulated transfection solutions manipulating ratios of DOPE and
DDAB, and observed 12–15% gene delivery in human corneal fibroblasts in vitro, and
rodent and rabbit stroma in vivo after corneal administration via a defined delivery technique
(Mohan et al., unpublished data). Gene delivery in cultured human epithelial cells and in
rabbit corneal epithelium in vivo has also been reported with DOTAP/DOPE transfection
mixture (Toropainen et al., 2007). A formulation of liposomes and transferrin was shown to
modulate chemokine expression with viral macrophage inflammatory protein II in a murine
model of corneal allograft rejection (Pillai et al., 2008). Transferrin was used to enhance
transfection efficiency by promoting endocytosis. Among cationic lipids/polymers,
polyethyleneimine (PEI), poly-lactide-co-glycolide (PLGA), polylactic acid (PLA), and
chitosan have been evaluated for corneal gene transfer. PEI showed significant transgene
delivery in cultured human corneal epithelial and rabbit cornea in vivo (Hornof et al., 2008;
Yuan et al., 2006). Chitosan, a naturally occurring aminopolysaccharide resulting from
alkaline deacetylation of chitin, has been examined widely for gene transfer because of its
non-toxic nature at high concentrations, high availability, low cost, and biodegradable
character. Several studies have reported successful delivery of genes in ocular tissues,
including the cornea, using chitosan (de la Fuente et al., 2008a, b). Nonetheless, many
challenges such as poor transfection, significant immune reaction, cell-targeting etc. remain
to be resolved for its wider application as a useful delivery system (Xu et al., 2010).
2.3 Next generation AAV and nanoparticle vectors
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To overcome the obstacles presented by conventional viral and nonviral vehicles many new
vectors considered next generation were developed. Discussing all of these is beyond the
scope of this review. Herein we focus our attention on tyrosine mutant AAV, nanoparticles,
and dendrimers which have shown promise for corneal gene therapy in preclinical animal
studies.
2.3.1 Tyrosine mutant AAV vectors—The AAV capsid surface is a fundamental
element involved in host receptor binding, cellular uptake, and intracellular trafficking (Van
Vliet et al., 2008) thus affecting transduction efficiency. Trafficking within the target cell
renders the AAV vector susceptible to natural cellular degradation mechanisms such as the
ubiquitin-proteasome pathway (Douar et al., 2001). Phosphorylation of AAV surface
exposed tyrosine residues marks the vector for ubiquitination and subsequent proteasomemediated degradation prior to entering the nucleus (Petrs-Silva et al., 2009). A recent study
presented evidence that phosphorylation of surface exposed tyrosine residues by epidermal
growth factor receptor protein tyrosine kinase (EGFR-PTK) significantly reduces
transduction efficiency of both single-stranded and self-complementary AAV2 vectors by
~68% and ~74%, respectively. In addition, intracellular trafficking is retarded due to AAV

Prog Retin Eye Res. Author manuscript; available in PMC 2013 January 1.

Mohan et al.

Page 10

NIH-PA Author Manuscript
NIH-PA Author Manuscript

ubiquitination followed by degradation mediated by proteasomes (Zhong et al., 2008). Sitedirected mutagenesis of each of the seven AAV2 capsid tyrosine residues (Y252, Y272,
Y444, Y500, Y700, Y704, and Y730) by phenylalanine residue substitution leads to
increased vector transduction and transgene expression by circumventing EGFR-PTK
phosphorylation and the ubiquitin-proteasome pathway in human cells in vitro and murine
hepatocytes in vivo (Zhong et al., 2008). These so-called next generation tyrosine mutant
AAV2, AAV8, and AAV9 vectors have several-fold higher transgene delivery in retinal
cells after subretinal or intravitreal injection compared to their wild-type counterparts (PetrsSilva et al., 2009). These results are also clinically applicable in the context of vector dose.
AAV2 vectors have been used in many Phase I/II clinical trials (Zhong et al., 2008).
However, relatively large vector doses are required to attain therapeutic levels and may
trigger an immune reaction. Neutralizing antibody levels are thought to be proportional to
virus dose and preexisting antibodies may reduce transduction efficiency upon vector readministration (Petry et al., 2008). Tyrosine mutant AAV vectors were shown to decrease
vector dosage needed for transduction. A potent tyrosine mutant AAV2 Y444F vector
showed superior transduction even at 10,000-fold lower titer compared to wild type AAV2.
The lower AAV dose also leads to a decreased immune response (Petrs-Silva et al., 2009).
Double, triple, and quadruple tyrosine-mutants have been generated to evaluate potential
augmentation of AAV transduction efficiency. In bone marrow-derived primary murine cells
and human mesenchymal stem cells, a triple AAV2 mutant consisting of Y444F, Y500F,
and Y730F mutations increased transduction efficiency by almost 130-fold and significantly
improved viral intracellular trafficking (Li et al., 2010). Our laboratory examined the
efficacy of tyrosine-mutant AAV2, AAV8, and AAV9 vectors in delivering genes to the
stroma and tyrosine-mutant AAV8 to the endothelium of the mouse cornea in vivo. In our
studies, we utilized hairdryer-based topical application technique for achieving targeted
delivery into the mouse stroma (Mohan et al., unpublished data) and specialized
microinjection techniques to introduce the AAV8 vector encoding GFP into the anterior
chamber of mice eyes (Sharma A, et al. IOVS 2010;51:ARVO E-Abstract 2839). All the
three tested tyrosine-mutant AAV serotypes showed significantly higher transgene delivery
in the mouse stroma in vivo compared to their corresponding wild type in preliminary
studies (Mohan et al., unpublished data). The tyrosine-mutant AAV8 vector demonstrated
substantially greater marker gene delivery than the wild type AAV8 vector (Fig. 5) into the
corneal endothelium of mouse eye in vivo with no apparent adverse effects.
Stereomicroscopy, immunocytochemistry and slit lamp biomicroscopy were used to analyze
the efficacy and safety of screened vectors. Our recent studies showing substantial targeted
gene delivery into corneal endothelium are particularly exciting as it has potential as an
effective therapy for endothelial dystrophies in the future.
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2.3.2 Nanoparticle vectors—The National Institutes of Health coined the term
nanoparticles (NPs) for materials 1–100 nm in size used in medicine for disease diagnosis
and therapy. The advances in nanotechnology have supplied a large reservoir of NPs that
may well revolutionize the future of medicine. Smaller than 100 nm in size, NPs are
minuscule and thus able to access anywhere within the in vivo realm, as living cells are
10,000–20,000 nm in diameter (Sharma et al., 2010a). Additionally, the ability of NPs to
multiplex and incorporate a myriad of ligands such as DNA, antibodies, peptides, and
probes can give rise to an array of therapeutic modalities. Internalization of NPs in
mammalian cells is carried out by phagocytosis, macropinocytosis, clathrin- or caveolaemediated endocytosis, and other clathrin- and caveolae-independent endocytic pathways
(Ragusa et al., 2007; Hillaireau and Couvreur, 2009).
Many studies reported gene transfer in non-ocular cells with metallic (gold), polymeric (PEI,
poly-L-lysine, PLGA), or hybrid (metallic-polymeric) NPs (Ragusa et al., 2007; Ghosh et
al., 2008). Limited studies investigated the prospective of NPs for delivering genes in the
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eye, including the cornea (Cai et al., 2008; de la Fuente 2008a, 2008b; Sharma et al., 2011).
An in vivo study showed marker gene delivery in the retina, lens, trabecular meshwork, and
cornea with PEG-substituted-30mer lysine NPs (Cai et al., 2008). These NPs provided shortterm transgene expression, and may necessitate repeated applications for sustained effect.
NPs made from PLGA have been shown to deliver significant transgene in cultured rabbit
conjunctival epithelial cells (Qaddoumi et al., 2004). Chitosan NPs have been shown to
transfect up to 15% of human corneal epithelial and normal human conjunctival cells in
vitro without affecting cellular viability (de la Fuente 2008a, 2008b). Recently, a
nanodendritic compound was used as an in situ polymerizable adhesive in repairing a variety
of corneal wounds in the porcine and human eyes ex vivo without major side effects
(Grinstaff MW. IOVS 2008;49:ARVO E-Abstract 4801). A follow up in vivo study using
chicken eyes reaffirmed biodendrimer efficacy and suggested that it may be superior to
suturing (Berdahl et al., 2009). Our ongoing experiments with DOTAP NPs showed
significant delivery of GFP marker gene in cultured human corneal fibroblasts (up to 20%)
and human corneal endothelial cells (up to 14%), without compromising cellular viability
and proliferation (Fig. 6; Mohan RR, et al. IOVS 2007;48:ARVO E-Abstract 2733). One in
vitro study investigated a nanocarrier, comprised of biocompatible and bioadhesive
compounds hyaluronic acid (HA) and chitosan, as a vehicle for gene delivery to human
corneal epithelial and conjunctival cells (de la Fuente et al., 2008b). The NPs loaded with
plasmid encoding reporter gene, were internalized by ocular cells via hyaluronan receptor
CD44-mediated endocytosis as visualized by confocal microscopy and showed high levels
of EGFP expression (up to 15%) with undetectable negative impacts on cellular viability.
Reporter gene expression was directly proportional to HA content possibly due to improved
internalization, trafficking, and transcription brought about by the polysaccharide.
Interestingly, NPs composed of oligomeric HA yielded lower transfection than polymeric
HA NPs, although the opposite effect was noted for chitosan. The HA quantity in NPs also
affected cytotoxicity as increased HA levels were associated with a reduction in cellular
toxicity. Thus NPs made of high HA content combined with chitosan oligomers may greatly
improve gene transfer in ocular surface tissues. Later this group demonstrated transgene
expression in the cornea and conjunctiva in vivo for 7 days with HA-chitosan NPs using a
rabbit model (de la Fuente et al., 2008b). NPs were found to transfect more peripheral
corneal cells possibly as a result of NP accumulation in those regions. The results of this
study may have clinical application in eye drops for ocular surface abnormalities in the near
future. Recently marketed ultrapure chitosan oligomers (NOVAFECT) were used by
Klausner et al. (2010) as a blueprint in designing novel chitosan-based NPs with different
polycation nitrogen to DNA phosphate group (N/P) ratios as gene carriers for the cornea.
The chitosan-based NPs were intrastromally injected into rat corneas and successfully
transfected keratocytes in vivo (Klausner et al., 2010). The transfection efficiency of
chitosan and its derivatives is highly dependent on degree of deacetylation, molecular
weight of chitosan, pH, serum, cell type, and N/P ratio (Kim et al., 2007). The utility of PEI
nanometallic-conjugates for gene delivery has also been reported (Thomas and Klibanov,
2003). Gold nanoparticles (GNPs) are highly attractive as biocarriers because they are
nontoxic, inert, easy to synthesize, and can condense DNA efficiently (Pissuwan et al.,
2011). As gene transporters, GNPs have displayed significant marker gene delivery and
expression into many mammalian cells (Ghosh et al., 2008; Li et al., 2009; Zhou et al.,
2008; Thomas and Klibanov, 2003). PEI-gold nanoconjugate transfection efficiency and
toxicity largely depends on PEI molecular weight. These authors used 2kDa PEI (PEI2)
conjugated to GNPs and found that low molecular weight PEI increased nanoconstruct
transfection efficiency of COS-7 cells six times more than PEI25 (Thomas et al., 2005). In
addition, the synergistic action of PEI2-GNPs with N-dodecyl-PEI2 was also demonstrated
and showed increased gene delivery by 11 fold compared to PEI25. An observation of
paramount importance was the transfection of up to 50% cells with ternary complex,
whereas unmodified PEI2 and PEI25 showed 4% and 8% transfection, respectively. The use
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of PEI2-GNPs also resulted in higher cytotoxicity and was linked to the ability of PEI to
enter the nucleus. Subsequently these authors suggested that optimal N/P ratio is required
for high transfection and is dependant on several factors such as polycation molecular
weight, hydrophobicity, and degradability. The lower N/P ratio values are indicative of a
polycation’s superior ability to condense DNA and better in vivo gene delivery (Thomas et
al., 2005). PEI has been found to be toxic in vivo (Tiyaboonchai et al., 2003) and research is
underway to minimize its toxicity by chemical modifications (Lungwitz et al., 2005).

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Recently we assessed the efficiency of PEI2-GNPs for delivering genes in the human cornea
using an in vitro model. This was the first time hybrid GNPs were investigated for
delivering therapeutics in the cornea. In these studies PEI2-GNPs with N/P ratios of 60, 90,
120, and 180 showed significant gene transport in human corneal fibroblasts with no
negative effects on cellular viability or phenotype (Mohan et al., unpublished data). Sensing
the potential of this nanoconstruct for corneal nanomedicine, we performed an elaborate
study to evaluate PEI2-GNPs toxicity and safety for the cornea in vivo using a rabbit model.
PEI2-GNPs were topically applied onto the cornea using a cloning cylinder with and without
removing corneal epithelium once for a brief period of time ranging from 2–5 minutes
(Sharma et al., 2011). Cloning cylinders are available commercially and are made in various
sizes from a variety of materials such as glass, porcelain, stainless steel, etc (see Fig. 8A for
appearance). The cloning cylinder was used based on our previous experience as it enhances
vector delivery to corneal cells in a targeted region limiting its contact with neighboring
ocular tissues, and thus preventing unwanted NP entry into adjacent ocular cells. The rabbit
corneal tissues collected at 12 h, 72 h, or 7 d post-PEI2-GNP application displayed
substantial gold uptake in the rabbit cornea with a slow clearance of GNP over time (Sharma
et al., 2011). Transmission electron microscopy detected GNP in the extracellular matrix
(ECM) and keratocytes of rabbit corneas. Slit lamp biomicroscopy performed 7 days after
topical PEI2-GNP application revealed no corneal inflammation, redness, or edema in rabbit
eyes in vivo although some degree of discoloration in the eye was noted due to the presence
of GNPs (Fig. 7A). The effect of this discoloration on optical properties of the eye is still
unknown and requires further investigation. The rabbit corneas collected 12h after PEI2GNP application without removing corneal epithelium showed few TUNEL+ cells in the
stroma (Fig. 7B) whereas corneas that received GNPs after removing corneal epithelium
showed significant TUNEL+ cells (Fig. 7C). These results suggest that PEI2-GNPs are safe
for the cornea and have potential for delivering gene therapy to the cornea but certainly
demand more research in the area of GNPs clearance from the cornea and its effects on the
optical properties of the eye (Sharma et al., 2011). Past reports point to renal excretion as the
chief route of GNP clearance from the body (Hainfeld et al., 2006; De Jong et al., 2008).
Since the cornea lacks a vascular supply, this route of clearance is not available. We
postulate that GNPs are cleared from the cornea via slow diffusion into the tear fluid or
aqueous humor (Sharma et al., 2011).
NPs composed of human serum albumin (HSA), the most abundant plasma protein, have
been studied for gene delivery in the cornea (Jani et al., 2007). HSA complexed with
plasmid encoding a soluble trap for vascular endothelial growth factor (VEGF) was injected
into the mouse stroma three weeks prior to alkali injury. HSA NPs were detected in
keratocytes, showed transgene expression up to 5 weeks post injection, and reduced corneal
neovessel formation. Furthermore, no corneal inflammation, edema, opacity, or other
toxicity in corneas injected with HSA NPs was noticed during a three week observatory
period (Jani et al., 2007). It was reported that HSA NPs enter cells via caveolae- or clathrinmediated endocytosis, safeguard plasmid from DNase I- and vitreous humor-mediated
biodegradation, permit plasmid escape from lysosome entrapment, and lead to sustained
release of plasmid (>6 d in vitro) resulting in increased gene expression and activity (Mo et
al., 2007).
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2.3.3 Dendrimer vectors—Dendrimers, as the name suggests, are highly branched
molecules with the ability to envelope or complex other molecules such as DNA (Mintzer
and Simanek, 2009). The potential of dendrimers as drug delivery systems, antibacterial
agents, and bioadhesives in wound repair for the cornea have been investigated (Durairaj et
al., 2010; Degoricija et al., 2007; Berdahl et al., 2009; Calabretta et al., 2007). Activated
polyamidoamine dendrimers complexed with plasmid DNA have been shown to transfect 6–
10% of corneal endothelial cells after direct application to the cornea (Hudde et al., 1999).
Marano and colleagues reported inhibition of laser-induced new blood vessel formation in
rat eyes with no adverse effects by dendrimer-mediated delivery of anti-VEGF
oligonucleotide (Marano et al., 2005). However, the potential of dendrimers for corneal gene
transfer has not been investigated extensively.

3. Tissue-selective gene therapy tools
3.1 Vector engineering
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Different vectors have been engineered to attain tissue-selective targeted gene delivery to
corneal cells. A logical approach is to develop corneal cell specific vectors. However, such
vector engineering is a challenging undertaking and demands active research. Ideally, cornea
cell specific (epithelial, keratocyte, endothelial) vectors drive therapeutic gene expression in
a controlled and targeted fashion in the desired cells of the cornea making them safe and
effective for clinical applications of gene therapy. The use of tissue-specific promoters
cloned into viral and nonviral vectors can accomplish tissue selectivity (Klausner et al.,
2007). Although epithelial-specific (Shiraishi et al., 1998) and keratocyte-specific (Carlson
et al., 2004) promoters for the cornea have been described earlier in murine and rabbit
models, promoters with corneal endothelial cell specificity for gene therapy in vivo have yet
to be defined. The keratin 12 (epithelial-specific) and keratocan (keratocyte-specific)
promoters in conjunction with polymeric micelles were tested to deliver β-galactosidase
marker gene into the corneas of mice and rabbits in a non-invasive manner using eye drops
(Tong et al., 2007). This approach of using cornea-specific promoters in plasmids has
significantly enhanced transgene expression in targeted corneal cells (Tong et al., 2007).
Another approach for targeted gene therapy in the cornea includes usage of an inducible
strong promoter with a switch-on and -off mechanism (Williams and Coster, 2010). These
inducible promoters regulate activation and duration of gene expression, which is triggered
in the presence of a supplementary factor that is either released endogenously under
particular physiological conditions (e.g. ischemia) or administered exogenously (Bainbridge
et al., 2006). Bitransgenic mouse lines that over-express β-galactosidase in the corneal
epithelium upon induction with doxycycline have been characterized in the past (Chikama et
al., 2005). A gene-targeting construct with an internal ribosomal entry site–reverse
tetracycline transcription activator cassette was introduced into the keratin 12 gene (Krt12)
to generate a knock-in Krt12rtTA/+ mouse line. These knock-in mice were then bred with tetO-LacZ reporter mice to produce Krt12rtTA/+/tet-O-LacZ bitransgenic mice. Doxycycline
ingestion by these bitransgenic mice increased corneal reporter gene expression 15-fold. In
addition, β-galactosidase enzyme activity was detected 24 hrs post-antibiotic induction,
leveled out at 2 d, and returned to basal levels 4 wks after doxycycline was eliminated from
the diet (Chikama et al., 2005). Not only are studies of this nature extremely useful in
expounding signaling mechanisms of different growth factors and cytokines, but also in
clarifying the roles of various corneal genes under homeostatic and pathologic conditions
(Chikama et al., 2005). More recently, Parker et al. (2009) studied a glucocorticosteroidinducible promoter (GRE5) in a lentiviral vector encoding IL10 in A549 cells, and ovine and
human corneas in vitro (Parker et al., 2009). A549 cells cultured with dexamethasone
displayed a 30- to 40-fold increase in IL10 compared to controls while ovine and human
corneas demonstrated 9- to 10-fold increase as quantified with enzyme-linked
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immunosorbent assay. This study outlines the efficacy of a steroid-inducible promoter in
corneal gene transfer and paves the way for its application in future studies involving the
modulation of transgene expression in donor corneal allografts (Parker et al., 2009). Even
now, no ideal non-leaky cell-specific or inducible vectors are available for corneal gene
therapy although considerable progress has been made in this area.
3.2 Custom vector-delivery techniques
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Clinicians routinely perform simple surgical procedures such as epithelial scrape,
microinjection, etc in the cornea in the general eye clinic to treat corneal abnormalities. We
postulated a few years ago that an appropriate combination of vector and vector-delivery
techniques could be used for developing targeted gene therapies. The ideal vector-delivery
technique would involve minimal corneal injury during and/or following vector application
and have the ability to introduce the vector to a precise location in a controlled manner.
Methods such as intracameral delivery, intrastromal application, topical, and
subconjunctival administration have all shown promising outcomes. However, with the
exception of topical application and subconjunctival injection, all corneal gene transfer
approaches have been deemed invasive with damaging impacts on the integrity of the ocular
surface (Cheng et al., 2007). Even though topical application is the most acceptable
approach to deliver therapeutics to the eye due to its non-invasive nature, preservation of
corneal integrity, and minimal systemic side effects, the use of eye drops containing
macromolecules including genes for corneal delivery is ineffective without opening tight
junctions to enhance epithelial layer permeability (Cheng et al., 2007; Hao et al., 2010). Our
recent studies demonstrated that vector-delivery techniques play a role in gene delivery in
the cornea, and could be used as a tool to reduce contact of vector to unwanted tissue and
enhance target specificity (Mohan et al., 2010b). A few strategies we have used for this
purpose are shown in Fig. 8 and include cloning cylinder (8A) outlined previously, soaked
circular sponge (8B), and glass-capillary (8C). It is well known that corneal permeability
and hydration affect corneal transparency (Maurice, 1984). The dehydration of the cornea
with a hair dryer is a conventional method to treat Fuchs’ dystrophy in human patients
(Bainbridge 2008). We incorporated this technique currently in clinical use to dehydrate the
cornea in a controlled fashion to increase vector absorption (Mohan et al., 2010b). After
removing the epithelium via gentle scraping with a beaver blade, a technique commonly
used in refractive laser surgery, a state of corneal dehydration was promoted by applying a
hair dryer once, twice, thrice, or five times to blow warm air on the ocular surface for 10 s
with 5 s intervals. Balanced salt solution (BSS) or AAV8 vector encoding alkaline
phosphatase gene was then immediately applied topically for 2 mins with a custom-designed
cloning cylinder to mouse and rabbit corneas in vivo and human cornea ex vivo. We found a
statistically significant BSS/vector absorption ranging from 14–27% in corneas dried for 20,
30, and 50 s. AAV8-mediated transgene delivery was also increased with longer exposure to
the hairdryer. However, corneas that underwent prolonged drying for 50 s demonstrated
amplified infiltration of activated granulocytes as detected with CD11b immunostaining
whereas 30 s of hair dryer-supplied warm air did not trigger severe immune reaction or
jeopardize corneal morphology (Mohan et al., 2010b).
It has been long known that corneal epithelial injury induces apoptosis of keratocytes,
inflammation, and wound healing in the cornea (Mohan et al., 2003; Wilson et al., 2002;
Jester et al., 1999). Several researchers have demonstrated a cascade of cellular events
including cytokine and growth factor release following epithelial injury leading to varied
levels of corneal wound healing response (Mohan et al., 2003; Wilson et al., 2002; Jester et
al., 1999). Scores of clinical and animal studies have found distinctly different wound
healing responses in the cornea after surgical, mechanical, or chemical injury. Many
investigators including us have reported that injury to the corneal epithelium causes
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keratocyte apoptosis in the anterior stroma. However, no studies were performed to examine
whether the intensity of mechanical injury dictates the amount of keratocyte death in the
anterior stroma. Recently, we hypothesized that careful, gentle removal of the corneal
epithelium with a #64 surgical blade under controlled conditions induces clinically
insignificant keratocyte apoptosis and wound healing in the cornea in vivo contrary to rough
corneal epithelium removal with a #64 blade under undefined conditions. To test the
hypothesis we performed a very simple experiment using a rabbit model. In the same rabbit
eye, 5mm central corneal epithelial was gently removed following defined condition and
4mm peripheral corneal epithelium was removed in a rough manner with no defined
conditions with a #64 surgical blade. Fig.9 shows the TUNEL assay of the rabbit cornea
collected 24h after euthanasia. The detection of a few TUNEL+ cells in the central cornea
where the epithelium was removed by defined gentle technique and several TUNEL+ cells
in the peripheral cornea where the epithelium was removed by undefined rough technique
strongly support our hypothesis. Additional support to our hypothesis comes from our recent
hair dryer study in which we observed almost no inflammatory response in corneas
subjected to up to 3 rounds of 10s dehydration as a comparable quantity of inflammatory
cells were seen in murine corneas that did not experience hair dryer-assisted dehydration
(Fig. 4 Mohan et al., 2010b). Thus we hold that the administration of an efficient vector via
defined vector-delivery technique can successfully deliver therapeutic genes in the corneal
stroma in vivo without compromising corneal integrity or function. More research is
required to fully define parameters and techniques that minimize side effects, improve
safety, and augment targeted delivery of therapeutic genes into keratocytes or the stroma in
vivo with AAV vectors.
Delivering genes precisely into the corneal endothelium is a huge challenge and a major
limitation for developing gene therapy for corneal dystrophies such as Fuchs’ dystrophy, a
leading cause of corneal blindness with no effective treatments available. To address this
challenge we developed minimally invasive microsurgical techniques based on the principle
of air pressure force like a water gun as shown in Fig. 10. In our studies we found these
techniques improved target-specificity significantly potentiating transgene delivery into
mouse corneal endothelium in vivo. The newly optimized microsurgical procedures derived
from microinjection technique are simple and may be used routinely in ophthalmology but
may require practice to attain proficiency like all other surgical techniques.

4. Gene therapy updates in various corneal disorders
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Trauma, injury and/or infections to the eye lead to corneal dysfunction and vision
impairment. Corneal disorders are the 3rd leading cause of blindness in the world according
to the World Health Organization. Eight million people in the world, including 1.5 million
children, are blind due to corneal abnormalities (Whitcher et al., 2001). Corneal disease and
disorders have a broad range of pathology leading to diverse outcomes. Haze, scarring,
abnormal wound healing, new blood vessel ingrowth, conjunctivitis, dry eye, graft failure,
endothelial defects, and Fuchs’ dystrophy are prevalent corneal problems among many
acquired and genetic corneal diseases. Gene therapy holds great promise for treating as well
as preventing corneal diseases and disorders. In the field of corneal gene therapy emphasis is
more on treating common corneal disorders instead of curing genetic defects. Here we
provide an overview of the progress made in the field of corneal gene therapy with a brief
description about the disease condition/cause.
4.1. Corneal graft rejection
Keratoplasty is currently used for treating many corneal diseases. According to the Eye
Bank Association of America more than 42,600 corneal transplants were performed in the
United States in 2010 alone. Although perhaps the most successful transplant procedure, it is
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not without blemish. Corneal graft rejection due to immunological reaction is the chief cause
of failure despite the cornea enjoying an immune privilege status (Williams and Coster,
2010). Post-operative complications and lack of good quality donor corneas are the other
concerns. Gene therapy approaches have been tested to improve allograft survival by
delivering various therapeutic genes to modulate cellular transport, apoptosis, angiogenesis,
and wound healing in vivo (Williams and Coster, 2010). In 2006, the Larkin group reported
the delivery of indoleamine 2,3-dioxygenase (IDO) in murine corneal endothelium with
lentivirus vector (Beutelspacher et al., 2006). An increase in IDO mRNA and protein levels
was detected and IDO expression was found to be intracellular and restricted to the
endothelial layer of the cornea. Ironically corneal endothelial pathology accounts for almost
48% of penetrating keratoplasty. Once activated, IDO, an intracellular enzyme, induced by
pro-inflammatory cytokines like interferon (IFN) and TNF, leads to the immunoregulatory
catabolism of tryptophan via opening of the essential amino acid’s indole ring forming Nformylkynurenine and subsequently L-kynurenine (Higuchi and Hayaishi, 1967). The IDOmediated diminution of tryptophan, in addition to the extracellular release of tryptophan
catabolites, is believed to halt activated T cells in the cell cycle’s G1 phase encouraging
immune tolerance (Munn et al., 1999) and apoptosis essential to the survival of transplanted
corneas. Full thickness corneal grafts were also used by the Larkin group to study vectormediated IDO over-expression (Beutelspacher et al., 2006). The study demonstrated
significant prolongation of corneal allograft survival after IDO transduction of excised donor
cornea ex vivo prior to transplantation compared to GFP and non-IDO-transduced control
corneas (Beutelspacher et al., 2006). This demonstrates the potential of IDO gene therapy to
thwart corneal allograft rejection. A year later in 2007, the Dana group reported the use of a
lentivirus vector to over-express four anti-apoptotic genes (bcl-xL, bcl-2, survivin and p35)
in a rodent corneal transplantation model. They found that lentivirus-mediated transfer of
bcl-xL gene was not only effective at inhibiting apoptosis in the corneal endothelium in
vitro, but also significantly enhanced corneal graft survival in vivo as a 90% success rate
was observed at 8 weeks post-transplantation compared to 40% in uninfected controls and
30% in reporter gene controls (Barcia et al., 2007). More recently, the same group studied
lentivirus-driven bcl-xL and p35 gene delivery in both primary human endothelial cells and
human corneas, and found both genes displayed anti-apoptotic properties in the corneal
endothelium although p35 had greater anti-apoptotic efficiency than bcl-xL (Fushsluger et
al., 2011). It is also believed that gene therapy at earlier steps like the sensitization of host to
foreign antigen may be more efficacious (Williams and Coster, 2010). Other potential gene
therapy approaches include utilizing IL4, IL10, CTLA4-Ig, p40-IL12, viral MIPII, and nerve
growth factor (Willaims and Coster 2010).
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Another avenue for the utilization of gene therapy with regard to corneal transplantation
involves corneal endothelial cell density maintenance in corneal tissue procured and stored
at eye banks. Recombinant adenovirus-driven over-expression of transcription factor E2F2
ex vivo demonstrated increased endothelial cell count in rabbit and human corneas (Joyce et
al., 2004; McAlister 2005). Endothelial cells, normally amitotic, progressed through the cell
cycle from G1 to S phase in significant quantities accounting for the boost in the monolayer
cell density. E2F2 expression was short lived with expression dropping off 7 d following a 2
hr vector exposure (McAlister et al., 2005). This has great potential in not only the longterm preservation of corneas but also the donation of corneas with low endothelial density
previously considered unsuitable for keratoplasty involving endothelial replacement. In
addition, the benefits of the vector-mediated transfer of E2F2 may prove beneficial in the
treatment of corneal endotheliopathies.
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Wound healing plays a central part in the maintenance of corneal transparency and thus
normal vision. Corneal injury, regardless of cause, may ignite a dysregulated wound healing
response that commonly leads to corneal fibrosis and loss of visual function. Corneal wound
healing is an extremely intricate process under the regulation of several cytokines and
growth factors. Among several cytokines transforming growth factor beta (TGFβ) has been
identified as a chief player in the formation of a myofibroblasts and opacity in the cornea.
Thus, it has become a prime target for gene therapy aimed at preventing corneal scarring and
other corneal disorders caused by TGFβ. Many investigators share the thought that impeding
TGFβ or its signal transduction represents a powerful strategy to modulate uncontrolled
corneal healing and prevent or even cure corneal scarring. Recently, using an in vitro model
our laboratory demonstrated that decorin over-expression in human corneal fibroblasts
significantly inhibits TGFβ-driven keratocyte differentiation to myofibroblasts without
compromising cellular viability (Mohan et al., 2010a). Decorin, a member of the small
leucine-rich proteoglycan family, is expressed in the corneal stroma and plays an important
role in wound healing and structural support in the cornea (Mohan et al., 2011a). Using laser
capture technique, we found that photorefractive keratectomy-induced laser injury to the
cornea does not alter decorin significantly but dramatically increases TGFβ levels in the
rabbit cornea, in vivo (Tandon et al., 2010). This observation concurs with our hypothesis
that AAV-mediated decorin gene therapy can effectively reduce corneal scarring in vivo.
Indeed, in a very recent study we detected significant inhibition of corneal scarring in the
rabbit eye (59–73%; p <0.001 or <0.01) with no adverse effects at one-month time point
with AAV5-mediated decorin gene therapy (Mohan et al., 2011b). This study was the first to
demonstrate the therapeutic potential of decorin for treating corneal diseases via targeted
gene therapy (Fig. 11). Sensing the translational potential of AAV-mediated decorin gene
therapy for corneal scarring we are studying whether long-term targeted over-expression of
decorin cause any complication to the eye or changes in corneal function or transparency.
The clinical and slit lamp examination in the eyes of live rabbit at up to 4 months showed no
sign of adverse effects indicating that decorin gene therapy is safe for patients (Mohan et al
unpublished data). The pending histological, immunochemical, molecular and transmission
electron microscopy studies will validate this notion.
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Venturing to block specific targets in TGFβ signaling is another approach used by scientists
to develop corneal fibrosis treatment. Numerous studies have shown that TGFβ uses the
Smad-pathway to relay its signal to the nucleus leading to fibrosis (Tandon et al., 2010). The
translocation of Smad2 and Smad4 proteins during corneal wound healing in vivo has been
demonstrated by performing keratectomy and epithelial debridement wounds in SpragueDawley rats (Hutcheon et al., 2005). This study motivated us to perform in vitro studies with
Smad2, Smad3, Smad4, and Smad7 siRNA to examine whether TGFβ in human corneal
fibroblast cells relays its signal via the Smad pathway. The results of our study showed that
TGFβ-mediated keratocyte transdifferentiation to myofibroblasts occurs via Smad signaling
and that Smad7 is an attractive target to prevent myofibroblast formation. Our findings are
in accord with many literature reports as Smad7 gene therapy has been reported to inhibit
fibrosis in many non-ocular tissues such as kidneys, peritoneum, liver, etc. (Chen et al.,
2011; Dooley et al., 2003). Recently, Galiacy et al. (2011) used gene therapy strategies to
hinder excessive collagen deposition in corneal scar development. Using a recombinant
AAV-based vector (AAV2/8) the researchers overexpressed a specific fibril collagenase,
matrix metalloproteinase (MMP) 14, to prevent collagen deposition and subsequent scarring
following incisional injury to the cornea in mice. After microdissecting a 0.75 mm fullthickness button from the central corneal region, a single injection of 10 ul PBS into the
stroma in control mice was performed (vector was injected 10 hours prior to incisional
injury in the case of AAV2/8-GFP and AAV2/8-MMP14). This previously outlined model

Prog Retin Eye Res. Author manuscript; available in PMC 2013 January 1.

Mohan et al.

Page 18

NIH-PA Author Manuscript

encourages the fibroproliferative response during repair including the development of alpha
smooth muscle actin (αSMA)-expressing myofibroblasts from stromal keratocytes (Stramer
et al., 2003). The investigators demonstrated that a single intrastromal injection with
recombinant AAV-MMP14 mediated murine stromal keratocyte gene expression. This was
evident with decreased mRNA expression of αSMA and type III collagen, two key gene
markers of corneal fibrosis (Galiacy et al., 2011). MMP, like TGFβ, also has important
implications in other processes such as neovessel formation.
4.3 Corneal neovascularization
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Neovascularization may occur in any of the layers of the cornea following ocular trauma,
infection, injury, etc. and leads to corneal opacity. The sprouting of new blood vessels in the
cornea from the limbus is closely linked to the inflammatory response and poses a major risk
for corneal allograft rejection (Klausner et al, 2007). The mechanism of neovascular
formation and regression is tremendously complex involving a slew of cytokines, growth
factors, and cell types. However, it is widely accepted that vascular endothelial growth
factor (VEGF) plays a pivotal role in the development of new blood vessels. A welldesigned study performed by the Ambati group reported that the avascular phenotype of the
cornea is due, at least in part, to soluble VEGF receptor-1(sVEGFR-1) or sflt-1, an
endogenous trap for VEGF (Ambati et al., 2006). Thus patients with aniridia and mutations
in Paired box gene 6 (PAX6) lack sflt-1 and display spontaneous corneal neovascularization
(CNV). Gene therapy with sflt-1 may greatly benefit patients with these types of corneal
disturbances. Five years earlier in 2001, Lai and cohorts conducted a study in a rat model
showing the inhibition of CNV with recombinant adenovirus-mediated delivery of sflt-1
(Lai et al., 2001). Gene therapy utilizing sflt-1 may certainly prove beneficial in averting
VEGF-induced neovascularization in the setting of corneal graft rejection and other corneal
disorders. A variety of gene therapy methodologies have been probed to stem corneal
angiogenesis using experimental models and different transgenes that target VEGF such as
decorin, angiostatin, PEDF, vasohibin-1 and VEGF receptors Flt-1 and Flk-1 (Cheng et al.,
2007; Jani et al., 2007; Lai et al., 2007; Oh et al., 2010; Kuo et al., 2009; Yu et al., 2007;
Zhou et al., 2010; Mohan et al. 2011b). Adenovirus-mediated gene transfer of soluble VEGF
receptor-2, sFlk-1 was shown to inhibit VEGF-stimulated proliferation of murine and human
umbilical vein endothelial cells (Yu et al., 2007). The same study demonstrated that CNV
development in rats in vivo following cauterization is suppressed by anterior chamber
injection of adenovirus delivery of sFlk-1 (Yu et al., 2007). Immunohistochemistry studies
of corneas from these animals showed localization of protein production in the stroma and
endothelium 14 days following cauterization compared to absent sFlk-1 expression in
controls (adenovirus-null and adenovirus-GFP). This strongly suggests that adenovirus gene
therapy has the ability to transduce corneal cells of the endothelial and stromal layers with
sFlk-1, a vital element in the development of angiogenesis (Yu et al., 2007).
Gene therapy strategies using endostatin have also shown promise in treating CNV.
Endostatin, a naturally occurring fragment of collagen type XVIII, blocks endothelial cell
adhesion, migration and proliferation, and inhibits apoptosis (O'Reilly et al., 1997). Mice
eyes treated via single subconjunctival injection with recombinant AAV encoding endostatin
following silver nitrate cauterization to induce CNV showed significant inhibition of corneal
angiogenesis. Endostatin released from the conjunctiva suppressed the migrating limbal
vasculature, was detected at 4 days post-injection, and retained stable levels for more than 8
months. Interestingly no difference in immune response (measured by CD4 and CD8
lymphocyte staining) was noticed in mice treated with recombinant AAV-GFP injection,
PBS injection, and no injection (Lai et al., 2007).
Another gene therapy approach to obstruct VEGF-induced CNV development utilized
intrastromal injection of intraceptors linked to the endoplasmic reticulum retaining peptide
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KDEL. Plasmids encoding for specific VEGF binding domains of sFlt-1, Flt23K and
Flt24K, coupled to KDEL were delivered via pCMV vector and were shown to interrupt
VEGF signaling in vitro and in vivo. These peptides offset intracellular VEGF as they are
not liberated from the cell into the extracellular milieu. Interestingly a variation in VEGF
downregulation was seen between the two intraceptors with Flt23K suppressing injury
induced CNV by 66.8% and Flt24K by almost 50%, possibly due to differences in protein
configuration (Singh et al., 2005). The same group then tested the ability of Flt23K to
impede corneal neovessel growth using albumin nanoparticles and showed CNV regression
up to 40% at 5 weeks post intrastromal injection in a murine model (Jani et al., 2007).
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Recently Chen and cohorts evaluated gene therapy with multiple genes known to have
antivasculogenic activity in a murine model of CNV (Chen et al., 2010). Retrovirus
encoding murine sFlk-1, sTie2, and endostatin genes was used in cell cultures of human
umbilical vein endothelial cells (HUVEC) as well as in vivo studies involving
subconjunctival injection of vector into corneas of C57B1/6 mice with chemically induced
CNV. Studies in vitro showed decreased HUVEC proliferation with obvious additive effects
when two or three genes were combined (i.e. sFlk-1/sTie2, msFlk-1/endostatin, sTie2/
endostatin, sFlk-1/sTie2/endostatin). However, although HUVEC migration was also
decreased by these genes individually, the additive effect seen in proliferation was absent
highlighting the various pathways involved in these intricate processes of CNV. For the in
vivo segment of the study, gene combination showed efficient CNV inhibition specifically
downregulating levels of IL-1β, MMP-9, and VEGF as measured by western blotting and
RT-PCR. In addition, the combinations of sFlk-1/endostatin and sFlk-1/sTie2/endostatin
were found to significantly decrease nuclear factor (NF)-κB phosphorylation and super
repressor inhibitor kappa Bα (IkBα) expression without regard to total NF-κB quantity
(Chen et al., 2010). This has direct implications to CNV as NF-κB leads to VEGF
expression while IkBα inhibits NF-κB by maintaining it in an inactive complex in the
cytoplasm (Josko and Mazurek, 2004; Karin, 1999).
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Combining genes to thwart CNV is not a new concept. For example, an almost decade old
report from Casey Eye Institute evaluated lentivirus transfer of a fusion protein in an
allogenic transplantation model of CNV. Lentivirus was employed to transfect rabbit corneal
buttons ex vivo with a fusion gene made up of endostatin and the kringle 5 domain of
plasminogen. This small specific plasminogen fragment is known to display robust
inhibition of angiogenesis. Corneas transduced with the endostatin and kringle 5 fusion
protein showed decreased proliferation and migration of endothelial cells and subsequently
less postoperative neovascularization and inflammation in comparison to controls (Murthy
et al., 2003). Other kringle elements have also been assessed for their antiangiogenic
properties. Angiostatin is a product of proteolytic cleavage that comprises the first four
kringle domains of plasminogen. One group examined the role of subconjunctival injection
of AAV carrying angiostatin in a rat model of alkali-induced CNV. The researchers
illustrated corneal gene transduction of angiostatin and a post-operative day 7 mean CNV
area of 15.83±0.55 mm2 in untreated controls and 6.87±2.23 mm2 in angiostatin treated
animals reflecting 56.6% abatement of CNV due to angiostatin (Cheng et al., 2007).
In another study, mouse corneas were transfected with DNA plasmid encoding IL18 using
intrastromal injection. The angiostatic property of IL18 is well known making it potentially
useful in the treatment of ocular disorders associated with CNV such as herpes keratitis. The
investigators showed a decrease in VEGF production in IL18 treated eyes and subsequently
a weakened immunoinflammatory response compared to controls. Furthermore, bFGF
induced MBE cell lines treated with IL18 demonstrated diminished VEGF production and
gene expression in contrast to cells incubated with OVA (Kim et al., 2005).
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Vasohibin-1, an endothelium-derived negative feedback modulator of neovessel formation
characterized by Watanabe, has also been studied in gene therapy studies as a means to
inhibit CNV (Watanabe et al., 2004; Zhou et al., 2010). A 2010 report by Zhou and
colleagues described the subconjunctival injection of adenovirus encoding vasohibin-1 that
resulted in significant CNV reduction. It was speculated that the antiangiogenic nature of
vasohibin-1 may be related to the downregulation of VEGF type 2 receptor (Zhou et al.,
2010).
Other gene transfer studies have assessed the utility of CD36 (Mwaikambo et al., 2006),
pigment epithelium derived factor (Kuo et al., 2009), and GA binding protein (Yoon et al.,
2009) among other approaches to treating CNV. Future experiments may include vector
mediated delivery of inhibitors of angiogenesis derived from basement membrane such as
neostatin, restin, arresten, canstatin, and tumstatin (Ellenberg et al., 2010). Recently, our
laboratory detected significant CNV reduction in rabbit eyes after targeted decorin gene
therapy using AAV5 vector (Mohan et al., 2011c). CNV in rabbit eyes was induced by
VEGF implantation and AAV expressing decorin or GFP gene was topically applied for two
minutes on the rabbit cornea one day after VEGF implantation. As shown in Fig. 12,
targeted decorin delivery in the stroma showed (52–66% p<0.05, p<0.001 or p<0.01)
reduction at various stages of CNV in rabbit model (Mohan et al., 2011c).
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4.4 Corneal alkali burn
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Alkali burn injury to the cornea is a major clinical entity that leads to sight-threatening
sequelae such as corneal scarring, neovessel formation, and ulceration. Scores of preclinical
studies have been dedicated to finding ways to halt the progression of these negative after
effects of alkali burn. In 2007 the Saika group outlined the use of adenovirus to introduce
peroxisome proliferator-activated receptor-γ (PPARγ) to keratocytes in a mouse alkali burn
model (Saika et al, 2007). Gene therapy employing PPARγ, a nuclear hormone receptor with
immunomodulatory functions, has been evaluated extensively for non-ocular tissues (Lewis
et al., 2008; Klotz et al. 2009; Kulkarni et al., 2011). In the cornea, a faint expression of
PPARγ was noted via immunohistochemistry in the undamaged corneal epithelium as well
as corneas subjected to NaOH and treated with Cre-adenovirus. Conversely PPARγ in
burned corneas treated with adenovirus-PPARγ showed strong protein expression in stromal
and newly generated epithelial layers (Saika et al., 2007). PPARγ inhibited TGFβ1-induced
fibroblast to myofibroblast transdifferentiation as well as the production of profibrogenic
factors TGFβ1, TGFβ2, and connective tissue growth factor (CTGF) in addition to collagen
type Iα2 and MMP2/9. Corneal epithelium recovery and reconstruction of the basement
membrane were also encouraged by PPARγ gene delivery in healing mice corneas in vivo.
This study also showed that in the cornea PPARγ blocks a critical step in Smad signaling,
the nuclear entry of phosphorylated Smad2/3 (Saika et al., 2007). Another study from same
authors reported that adenovirus-mediated Smad7 overexpression in a murine eye
accelerated corneal wound healing and restricted corneal opacity (Saika et al., 2005a).
Furthermore, adenovirus introduction of bone morphogenic protein 7 (BMP7) was found to
promote corneal reepithelialization, inhibit myofibroblast production and monocyte/
macrophage infiltration, as well as downregulate TGFβ, MCP-1, and collagen expression in
the stroma (Saika et al., 2005b). BMP7 over-expression activated Smad1, 5, and 8 and partly
inhibited phosphorylated Smad2. However, it was unsuccessful at suppressing levels of
VEGF and the development of NaOH-induced CNV (Saika et al, 2005b). Apparently, none
of the previously discussed studies investigated the downside of PPARγ, SMAD7, or BMP7
gene transfer in the cornea as no information regarding side effects or adverse reactions has
been reported.
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Corneal inflammation due to ocular herpes simplex virus (HSV) infection, or herpes stromal
keratitis (HSK), is a leading cause of infectious blindness worldwide particularly in more
developed nations including the U.S. Recurrent infections often lead to corneal scarring,
neovascularization, and thinning resulting in visual abnormalities and blindness (Kaye and
Choudhary, 2006). Many studies have shared the common goal of developing a vaccine
using gene transfer technology to enhance protection against ocular HSV. These studies
have used individual HSV-1 glycoproteins (i.e. gD) as well as a cocktail of glycoproteins
and have shown variable success in controlling HSV keratitis (Sharma et al., 2010a). The
recent development of a humanized HLA-Tg rabbit model will hopefully assist in the design
of future vaccines for HSV-1 keratitis as it demonstrates spontaneous HSV reactivation
leading to recurrent HSK comparable to what is seen clinically. Moreover, this rabbit model
expresses human, rather than rabbit, HLA class I proteins (Hu et al., 2006; Dasgupta et al.,
2009).
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In the past siRNAs and RNA enzymes have shown promise in cell culture experiments but
their instability in vivo has been a barrier to their translation into clinical use. A group of
researchers from different medical disciplines at the University of Florida converged to
engineer a hammerhead ribozyme with a specific target, the mRNA of an essential late
HSV-1 gene, UL20. Ribozymes are RNA molecules that possess the ability to catalyze the
cleavage and formation of covalent bonds in RNA strands at specific sites. The
“hammerhead” motif is the smallest (approximately 30-nucleotides long) and best
characterized small catalytic ribozyme (Citti and Rainaldi, 2005, Mulhbacher et al., 2010).
Gene-tailored ribozymes have been designed, produced, and given to cells to knock down
the expression of specific genes (Citti and Rainaldi, 2005)..The investigators in the
aforementioned study used iontophoresis and an adenovirus vector to deliver the ribozyme
in rabbit skin cells in addition to rabbit eyes in vivo and discovered significant ribozymeinduced UL20 inhibition leading to a subsequent decrease in viral load in vitro and
decreased ocular HSV-1 severity in vivo (Liu J, et al. IOVS 2006;47:ARVO E-Abstract
3080). A follow up study by the same group used the ribozyme to decrease HSV-1 severity
in a murine footpad model (Liu et al., 2008b). These findings give credence to the value of
RNA gene therapy for HSV-1 by targeting late genes required for HSV-1 survival and may
find a niche in the treatment of ocular herpes including HSK in the future. Another group
used gene gun method to deliver gold particles carrying plasmid DNA encoding specific
interleukins to determine effect in HSK. A one time low dose (1 µg/shot) of IL4 or IL10
plasmid DNA was found to significantly abrogate the clinical course of HSK when
administered at 300 psi helium pressure with minimal alterations in immune response
systemically. IL6, shown to play a role in HSK development (Banerjee et al., 2004), was
also downregulated. In addition, gene gun utilization did not lead to significant corneal
damage as ascertained by histology and clinical examination (Bauer et al., 2006).
Diabetic disease of the cornea is a common occurrence in patients with type I and II diabetes
mellitus and can lead to sight-threatening corneal neuropathy and epitheliopathy. Currently,
no treatment exists to thwart the progression or cure the disease and treatment regimens are
largely symptomatic. Saghizadeh et al. (2010) recently used recombinant AV to overexpress
the hepatocyte growth factor (HGF) receptor c-met proto-oncogene in corneal epithelium of
diabetic human corneas in vitro. Their past studies outlined disturbances in HGF/c-met
signaling in diabetic corneas as c-met expression was reduced in the face of upregulated
HGF expression (Saghizadeh et al., 2005). With the introduction of exogenous c-met via
recombinant AV vector they reported improved reestablishment of HGF signaling and
subsequent restoration of marker protein patterns and enhanced wound healing (Saghizadeh
et al., 2010).
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Mucopolysaccharidosis (MPS) is a set of metabolic disorders characterized by the inability
to breakdown glycosaminoglycans (GAG) due to lysosomal enzyme deficiency. GAGs thus
accumulate in lysosomes systemically as well as in the eyes (Ashworth et al., 2006). MPS
VII, or Sly disease, is due to β-glucuronidase (GUSB) insufficiency leading to the
stockpiling of GAGs (dermatan, heparan, and chondroitin sulphate) while MPS VI, or
Maroteaux–Lamy syndrome, results from aryl N-acetylgalactosamine-4-sulfatase deficiency
leading to accumulation of dermatan sulphate (Ashworth et al., 2006). Pathology is common
in the ocular system and results in visual impairment due to opacification of the cornea and
disorders of other ocular tissues (Ashworth et al., 2006). While lysosomal accumulation
occurs in the corneal endothelium, it is their storage in keratocytes that causes corneal
opacity (Williams and Coster, 2010). Systemic gene therapy using a retroviral vector has
been shown to avert GAG accrual and ensuing corneal clouding due to MPS using neonatal
canines (Wang et al., 2006; Traas et al., 2007; Ponder and Auricchio, 2010). Even 6.5–8
years following therapy, little or no corneal opacity was detected in dogs with MPS VII
(Ponder and Auricchio, 2010). Gene therapy may have a role as an alternative therapeutic
strategy for MPS disorders by introducing genes that encode for specific enzymes, such as
GUSB, clearing lysosome build up in the eye and other tissues.

5. Lessons learned from corneal genetic studies: humans and animals
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Advances in molecular biology have led to the identification of numerous genes and gene
mutations associated with dystrophic diseases of the cornea. Different modes of Mendelian
inheritance are evident in corneal dystrophies likely due to alterations in several genes
including CHST6, KRT3, TGFBI, and UBIAD1 (Klintworth, 2009). The TGFβ induced
gene (TGFBI), commonly known as βig-h3, encodes the TGFBI protein (TGFBIp or
keratoepithelin). Changes in the genomic sequence of TGFBI have been linked to several
dystrophies of the corneal stroma such as Lattice dystrophy type I, Reis-Buckler dystrophy,
Thiel-Behnke corneal dystrophy, granular corneal dystrophy type I, and granular corneal
dystrophy II (Avellino corneal dystrophy) (Runager et al., 2008; Klintworth, 2009). Indeed
38 different mutations in the TGFBI gene are responsible for various corneal dystrophies,
the majority being missense mutations (Runager et al., 2008). TGFBIp functions as a cell
adhesion molecule acting by way of integrins (α1β1, α3β1, αvβ3, etc) and elements of the
ECM including proteoglycans (i.e. decorin), fibronectin, and collagens (Runager et al.,
2008). The precise function of these interactions remains to be identified although TGFBIp
may play a role as a regulatory modulator between the ECM and cells found in its
supporting meshwork (Runager et al., 2008). Dystrophic corneas contain aggregates of
unknown makeup although increased TGFBIp has been detected in addition to clusterin, a
proaggregation protein, in Fuchs endothelial corneal dystrophy (Runager et al., 2008;
Jurkunas et al., 2009). A recent report identified the two corneal dystrophies, gelatinous
drop-like corneal dystrophy and spheroidal degeneration, in the same patient (Zhang and
Yao, 2010). Upon molecular genetic examination a new missense mutation in the tumor
associated calcium signal transducer 2 (TACSTD2) gene was unearthed (Zhang and Yao,
2010). Earlier it was found that alterations in the UbiA prenyltransferase domain containing
1 gene are responsible for Schnyder corneal dystrophy (Weiss et al., 2007). The corneal
endothelial defect was found to be caused, at least in part, by variations in the transcription
factor 4 (TCF4) gene (Baratz et al., 2010). The knowledge of gene localization is paramount
in creating an animal model of disease and treatment approaches via gene therapy.
Previously it was thought that type I and II macular corneal dystrophy were due to genetic
aberrations of carbohydrate sulfotransferase 6 (CHST6) in the epithelial layer (Abbruzzese
et al., 2004) and that limbal stem cell therapy might possibly offer benefits to patients in
terms of therapy. It was recently shown however, that CHST6 along with keratan sulfate are
chiefly the stromal products of keratocytes underscoring the need for therapeutic modalities,
including gene therapy, to target stromal keratocytes (Di Iorio et al., 2010).
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Nonetheless, the lack of in vivo animal models has sharply hindered progress in the
development of gene therapy options for patients suffering from corneal dystrophies (Weiss,
2010). Furthermore, the pathogenesis and localization of genes responsible for many of
these disorders has yet to be elucidated. Recently, an animal model mimicking human
corneal dystrophy was reported by Chen and colleagues in 2010. A mouse model of
congenital stromal corneal dystrophy, caused by a faulty decorin gene leading to corneal
clouding, was created utilizing a Cre-on approach. It was also surmised that mutations in
decorin accounting for the disorganized stromal architecture may be influenced by class II
SLRPs lumican and keratocan (Chen S, et al. IOVS 2010; 51:ARVO E-Abstract 3832). It is
conceivable that keratocytes may induce an increase in GAG chain and SLRP production to
offset deficiencies in stromal ECM GAGs or SLRPs brought about by genetic causes. The
tissue-selective targeted gene-based therapeutic approaches we are attempting to define for
the cornea have great potential for corneal genetic dystrophies.

6. Ocular gene therapy clinical trials: current status
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Currently 20 gene therapy trials for eye disease are listed on The Journal of Gene Medicine
Clinical Trial website. Out of 20 gene therapy clinical trials, 18 are directed towards retinal
disorders, 1 for glaucoma, and 1 for the cornea. The lone corneal gene therapy Phase I/II
clinical trial is focused on evaluating the safety and efficacy of a matrix-targeted retroviral
vector bearing a dominant negative cyclin G1 construct (Mx-dnG1) as adjunctive
intervention for superficial corneal opacity/corneal scarring. The findings of the clinical trial
assessing gene therapy for diseases of the cornea have not yet been published.

7. Future directions: regenerative medicine, nanomedicine and other
approaches
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The future of gene therapy for the cornea is very promising and involves different branches
of medicine including regenerative medicine and nanotechnology. Indeed, nanotechnology
will lead to the development of regenerative medicine, microsensors and feedback
apparatus, improved imaging in vivo, and artificial vision (Zarbin et al., 2010a).
Regenerative nanomedicine is a new field in medicine gaining widespread attention. It
entails the use of nanoparticles containing regulatory molecules such as gene transcription
factors that allow for cellular reprogramming in vivo (Zarbin et al., 2010a). Nanoparticles
may not only serve as vectors for therapeutic gene delivery but may also act as biocarriers of
genes which may assist in the diagnosis and monitoring of corneal disease. This process of
coupling disease diagnosis with targeted treatment is termed theragnostics and has enormous
potential in the ocular system including the cornea. For example, oxidative stress has been
implicated in numerous inflammatory, metabolic, traumatic, and iatrogenic corneal diseases
(Shoham et al., 2008). By coupling a therapeutic gene such as peroxidase, superoxide
dismutase, or catalase (as well as a marker gene like GFP) to nanoparticles capable of
activating antioxidant response element, one may produce a nano-device with dual
diagnostic-therapeutic effects enabling corneal cells to treat themselves following oxidative
damage (Zarbin et al., 2010b).
Fagerholm and colleagues recently reported the results of a clinical study in Sweden
involving corneal regeneration with recombinant human collagen. Recombinantly produced
human collagen type III was cross-linked with 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) and fashioned into substitutes with
human corneal dimensions. This biomimetic substitute was then transplanted into patients
following anterior lamellar keratoplasty. The investigators found that a cell-free corneal
substitute imitating the cornea’s unique ECM can successfully provide support for
endogenous restoration of corneal epithelium, stroma, and nerves. Of note was the absence
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of inflammation, neovascularization, or rejection that plagues recipients of human donor
corneas (Fagerholm et al., 2009). Although the study had a small patient population (n = 10),
it clearly highlights the safety profile of recombinant human collagen and cross-linking
methods (Fagerholm et al., 2009). Preliminary results from the study demonstrate improved
visual acuity, ocular surface quality, and corneal sensitivity in patients with a biomimetic
corneal substitute. These corneal substitutes may prove beneficial in circumstances
necessitating short-term or emergency corneal replacements, where availability of human
donor corneas is poor or nonexistent and where prostheses are unfavorable (Fagerholm et
al., 2009). In the future these biomimetic corneas may serve as efficient permanent corneal
replacements and a viable option to human corneal tissue in transplantation. These
substitutes in combination with single or multiple gene therapy may find a niche in the
treatment of recurrent CNV and other disorders of the ocular surface.
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Cell-based therapy for corneal diseases has also been examined. A study from the
Funderburgh group (Du et al., 2009) used stem cells isolated from adult human corneal
stroma to rectify stromal opacity due to SLRP lumican deficiency in mice via intrastromal
injection of cells. Stem cells subsisted in wild-type mice for months without host cell fusion
or provoking an immune T-cell response. Human stromal stem cells introduced into the
stroma of lumican-null mice with corneal opacity (similar in nature to that of scar tissue due
to disorganized stromal collagen) led to rectification of fibrillar collagen defects and stromal
thickness and restoration of corneal transparency (Du et al., 2009). Thus stem cell therapy
shows proof of principle in treating corneal disease through the regeneration of corneal
tissue in a safe and efficacious manner similar to organogenesis. The results of a remarkable
clinical study in Italy involving autologous limbal cell treatment were recently reported
(Rama et al., 2010). Currently limbal stem cells, a group of cells responsible for corneal
epithelial renewal and regeneration, are transplanted as a treatment for limbal stem cell
deficiency (Pellegrini et al., 2009). 112 patients with burn-related corneal destruction
associated with limbal stem-cell deficiency were treated with autologous limbal stem cells
cultivated on fibrin. Corneal transparency was restored in 76.6% of eyes up to 10 years after
corneal transplantation with limbal stem-cell grafts identifying limbal stem cell cultures as a
source of transplantable cells for treating corneal burns (Rama et al., 2010).
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Future studies involving gene therapy for corneal diseases may include non-coding RNA
(ncRNA). ncRNA includes several types of functional RNA molecules not translated into
proteins that play key roles in several cellular processes such as transfer RNA, ribosomal
RNA, small interfering RNAs, microRNAs, PIWI-associated RNAs, small nucleolar RNAs,
promoter-associated RNAs, and telomere specific small RNAs. It has been shown that
ncRNAs play a part in oncogenesis and may be a factor in molecular aberrations of other
diseases (Galasso et al., 2010).
In the recent past, toll like receptors (TLRs) have gained attention in the cornea as their
activation sets off a multifaceted signaling pathway instigating innate and adaptive
immunity generating inflammatory cytokines and co-stimulatory molecules (Redfern and
McDermott, 2010). The production of chemokines encourages corneal infiltration of
macrophages and neutrophils resulting in the functional loss of corneal epithelium, stroma,
and endothelium leading to the loss of corneal transparency and visual activity (Kanwar et
al., 2010). The modulation of TLR signaling via gene therapy methods may play a vital role
in blocking immune-mediated corneal graft rejection as well as aberrant wound healing
following corneal infection.
The future will reveal animal models of human corneal disease in which to test highly
efficient viral or nonviral vectors with low-immunogenicity and sustained transgene
expression in combination with cell-based therapy and regenerative approaches. Presently
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the cornea lags behind the retina in gene therapy for various reasons including lack of
animal models of inherited disease for experimentation. Currently available technologies are
likely nontoxic and effective, at least in the short term, with little further development
(Weiss, 2010).

8. Conclusions
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The last five to six years have brought about great progress and advancement in the field of
corneal gene therapy. The increased understanding of the molecular mechanisms and course
of inherited and acquired corneal diseases have allowed for the submergence of targets for
gene-based therapy. The testing of various viral and non-viral vectors and multiple delivery
systems has been the key to the success observed in various models of corneal disease. We
along with other investigators have examined the efficacy of gene therapy using in vitro, ex
vivo, and in vivo animal (equine, murine, canine, etc) and human corneal tissues, identified
several efficient AAV serotypes and nanoparticles, and defined simple minimally invasive
vector delivery techniques for delivering genes precisely into targeted cells (keratocytes and
endothelium) of the cornea in vivo. Furthermore, using a combination of vector and delivery
techniques, we have defined tissue-selected targeted gene therapy approaches for the cornea.
Although much of the corneal gene therapy investigations have been accomplished in
animals, there is a dearth of research that has been translated fully from bench to bedside
including the clinic. The progress in establishing corneal gene therapy clinical trials has
been meager compared to gene therapy trials conducted in other ocular tissues. Even though
the cornea is easily accessible for gene transfer, it is lagging far behind the retina in terms of
clinical application of gene therapy for human patients. The future is bright however, as
novel innovations and treatment approaches have proved effective in animal models (i.e.
rabbits) that closely resemble the human cornea in terms of anatomy, wound healing
response, and function.
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Over the past few years, much effort has been made to develop strategies for effective
delivery of DNA to the nucleus of target cells. The most pertinent question concerning the
success of gene therapy is “how to introduce therapeutic genes into target cells/tissues?”
Vectors are important tools for introducing foreign genes into cells and are one of the two
major determinants for the success of gene therapy, the other being gene delivery technique.
Several viral and non-viral vectors have been developed and each has its own advantages as
well as limitations. In addition, many vector-delivery techniques have been developed to
enhance vector efficiency and achieve target specificity. With the discovery of animal
models of human corneal disease and the combination of gene therapy approaches with stem
cell therapy and regenerative medicine, the cure for corneal blindness may well become a
reality within the next decade.
Article highlights
➢

Next generation AAV vectors for corneal gene therapy.

➢

Nanoparticles are promising nonviral vectors for corneal gene therapy.

➢

Delivery techniques role in tissue-targeted corneal gene delivery in vivo.

➢

Decorin gene therapy could be a potential treatment for corneal blindness.

➢

Translation of corneal gene therapy requires further research.
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Fig. 1.

Representative cytochemical staining images showing transduction efficiency of AAV2/6,
AAV2/8 and AAV2/9 vectors for human corneal fibroblasts. The alkaline phosphatase
marker gene (stained purple) and 30 h time point were used for comparison.
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Fig. 2.
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Quantification of AAV2/6, AAV2/8 or AAV2/9 mediated transgene delivery in mouse
stroma in vivo. The delivered alkaline phosphatase gene expression in the corneal tissue
sections was quantified digitally by measuring pixels of purple stained tissue in 4 × 104 µm2
tissue area. * p < 0.05 AAV6/AAV8/AAV9 compared to control, φ = p < 0.05 AAV8 to
compared to AAV6, Ω = p < 0.01 AAV9 compared to AAV6.
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Fig. 3.

Representative images showing AAV9 effects on immune reaction (measured by Cd11b)
and cell death (measured by TUNEL) in mouse corneas. Like control corneas (no AAV
treatment), few Cd11b+ and TUNEL+ cells were observed in AAV-treated mouse stroma.
The TUNEL + cells detected in the corneal epithelium were because of its replenishment via
apoptosis. The AAV6 and AAV8 showed similar results (data not shown). Nuclei are
stained blue with DAPI.
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Fig. 4.

Representative H&E staining images showing histology of mouse corneas subjected to air
drying and collected 14 days after AAV8 application. A: 0 s air-drying. B: 50 s air-drying.
Mouse corneas subjected to 50 s drying showed moderate or higher levels of morphological
changes in anterior stroma. C: shows digital quantification of delivered marker gene
expression detected at day 14 in mouse corneas in vivo. These corneas received 2 µl of
AAV8 vector immediately after 0, 20, 30, or 50 s of drying. *p<0.05 as compared to 20 s; ϕ
p<0.05 as compared to 30 s.
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Fig. 5.
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Representative stereomicroscopy (A) and immunocytochemistry in tissue sections (B)
showing tyrosine-mutant AAV8 mediated transgene delivery in corneal endothelium of
mouse eye in vivo. Dispensing of vector via custom delivery-technique fetched selective
gene delivery into corneal endothelium. Cell nuclei were stained blue with DAPI while cells
expressing GFP gene stained green.
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Fig. 6.
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Representative images showing GFP gene delivery by DOTAP nanoparticles in cultured
human corneal fibroblasts (A) and HPV16-E6/E7 transformed human corneal endothelial
cells (B). Cell nuclei were stained blue with DAPI while cells expressing GFP gene stained
green.
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Fig. 7.

Representative slit-lamp biomicroscopy (A) and TUNEL assay images (B and C) showing
PEI2-GNP toxicity to rabbit cornea in vivo. No opacity, redness, or inflammation was seen
but PEI2-GNP-treated corneas exhibited mild purple coloration (pointed with arrowhead)
due to GNP uptake. The rabbit corneas in which PEI2-GNP was applied after epithelial
removal (B) showed many TUNEL+ cells compared to the corneas that received transfection
solution without epithelial removal (C). Nuclei are stained blue with DAPI and TUNEL+
cells in red.
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Fig. 8.

Representative image showing various minimally invasive defined vector-delivery
techniques developed using cloning cylinder (A), soaked circular sponge (B), and glasscapillary (C) for targeted gene therapy approaches for the cornea.
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Fig. 9.
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Representative TUNEL assay images showing effects of epithelial removal on keratocyte
death by custom (A) and non-custom (B) epithelial scrape techniques in the rabbit corneas.
Few TUNEL+ cells were noted in customized-gentle scrape technique (A) compared to nonoptimized epithelial removal technique (B). Nuclei are stained blue with DAPI and TUNEL
+ cells in red.
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Fig. 10.

NIH-PA Author Manuscript

Representative images showing technique utilized for achieving preferential gene delivery
into mouse corneal endothelium in vivo.
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Fig. 11.

Representative stereomicroscopy (A, B) and α-smooth muscle actin immunostaining (C, D)
images showing corneal haze inhibition by targeted AAV5-decorin gene therapy in rabbits
in vivo. AAV5 viral titer (6.5×1012 vg/ml) was topically applied onto the cornea once for 2
minutes after PRK.
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Figure 12.

Representative stereomicroscopy (A, B) and H & E (C, D) images showing VEGF-induced
corneal neovascularization inhibition in rabbits in vivo by AAV5-decorin gene therapy.
Decorin gene was delivered in the rabbit stroma by a single topical application of AAV5
titer (5×1012 vg/ml) on the cornea for 2 minutes.
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